The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age

Shigemi Yoshihara, Toshikazu Tsubaki, Masanori Ikeda, Warren Lenney, Richard Tomiak, Takako Hattori, Kenichi Hashimoto, Toru Soutome, Shihona Kato

Research output: Contribution to journalArticle

Abstract

Background: Fluticasone propionate 50 μg/salmeterol xinafoate 25 μg (FP/SAL) is widely used in adults and children with asthma, but there is sparse information on its use in very young children. Methods: This was a randomized, double-blind, multicentre, controlled trial conducted in children aged 8 months to 4 years. During a 2-week run-in period, they all received FP twice daily. At randomization, they commenced FP/SAL or FP twice daily for 8 weeks. All were then given FP/SAL only, in a 16-week open-label study continuation. Medications were inhaled through an AeroChamber Plus with attached face mask. The primary end-point was mean change in total asthma symptom scores from baseline to the last 7 days of the double-blind period. Analyses were undertaken in all children randomized to treatment and who received at least one dose of study medication. Results: Three hundred children were randomized 1:1 to receive FP/SAL or FP. Mean change from baseline in total asthma symptom scores was –3.97 for FP/SAL and –3.01 with FP. The between-group difference was not statistically significant (P = 0.21; 95% confidence interval: −2.47, 0.54). No new safety signals were seen with FP/SAL. Conclusion: This is the first randomized, double-blind study of this size to evaluate FP/SAL in very young children with asthma. FP/SAL did not show superior efficacy to FP; no clear add-on effect of SAL was demonstrated. No clinically significant differences in safety were noted with FP/SAL usage.

Original languageEnglish
Pages (from-to)195-203
Number of pages9
JournalPediatric Allergy and Immunology
Volume30
Issue number2
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Safety
Asthma
Masks
Random Allocation
Double-Blind Method
Multicenter Studies
Salmeterol Xinafoate Drug Combination Fluticasone Propionate
Fluticasone
Confidence Intervals
Therapeutics

Keywords

  • asthma
  • child
  • combination therapy
  • double-blind
  • fluticasone propionate
  • randomized
  • salbutamol
  • salmeterol

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Immunology

Cite this

The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age. / Yoshihara, Shigemi; Tsubaki, Toshikazu; Ikeda, Masanori; Lenney, Warren; Tomiak, Richard; Hattori, Takako; Hashimoto, Kenichi; Soutome, Toru; Kato, Shihona.

In: Pediatric Allergy and Immunology, Vol. 30, No. 2, 01.03.2019, p. 195-203.

Research output: Contribution to journalArticle

Yoshihara, S, Tsubaki, T, Ikeda, M, Lenney, W, Tomiak, R, Hattori, T, Hashimoto, K, Soutome, T & Kato, S 2019, 'The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age', Pediatric Allergy and Immunology, vol. 30, no. 2, pp. 195-203. https://doi.org/10.1111/pai.13010
Yoshihara, Shigemi ; Tsubaki, Toshikazu ; Ikeda, Masanori ; Lenney, Warren ; Tomiak, Richard ; Hattori, Takako ; Hashimoto, Kenichi ; Soutome, Toru ; Kato, Shihona. / The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age. In: Pediatric Allergy and Immunology. 2019 ; Vol. 30, No. 2. pp. 195-203.
@article{793dcee3156845df9c5ae6ccc9e11930,
title = "The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age",
abstract = "Background: Fluticasone propionate 50 μg/salmeterol xinafoate 25 μg (FP/SAL) is widely used in adults and children with asthma, but there is sparse information on its use in very young children. Methods: This was a randomized, double-blind, multicentre, controlled trial conducted in children aged 8 months to 4 years. During a 2-week run-in period, they all received FP twice daily. At randomization, they commenced FP/SAL or FP twice daily for 8 weeks. All were then given FP/SAL only, in a 16-week open-label study continuation. Medications were inhaled through an AeroChamber Plus with attached face mask. The primary end-point was mean change in total asthma symptom scores from baseline to the last 7 days of the double-blind period. Analyses were undertaken in all children randomized to treatment and who received at least one dose of study medication. Results: Three hundred children were randomized 1:1 to receive FP/SAL or FP. Mean change from baseline in total asthma symptom scores was –3.97 for FP/SAL and –3.01 with FP. The between-group difference was not statistically significant (P = 0.21; 95{\%} confidence interval: −2.47, 0.54). No new safety signals were seen with FP/SAL. Conclusion: This is the first randomized, double-blind study of this size to evaluate FP/SAL in very young children with asthma. FP/SAL did not show superior efficacy to FP; no clear add-on effect of SAL was demonstrated. No clinically significant differences in safety were noted with FP/SAL usage.",
keywords = "asthma, child, combination therapy, double-blind, fluticasone propionate, randomized, salbutamol, salmeterol",
author = "Shigemi Yoshihara and Toshikazu Tsubaki and Masanori Ikeda and Warren Lenney and Richard Tomiak and Takako Hattori and Kenichi Hashimoto and Toru Soutome and Shihona Kato",
year = "2019",
month = "3",
day = "1",
doi = "10.1111/pai.13010",
language = "English",
volume = "30",
pages = "195--203",
journal = "Pediatric Allergy and Immunology",
issn = "0905-6157",
publisher = "Blackwell Munksgaard",
number = "2",

}

TY - JOUR

T1 - The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age

AU - Yoshihara, Shigemi

AU - Tsubaki, Toshikazu

AU - Ikeda, Masanori

AU - Lenney, Warren

AU - Tomiak, Richard

AU - Hattori, Takako

AU - Hashimoto, Kenichi

AU - Soutome, Toru

AU - Kato, Shihona

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Fluticasone propionate 50 μg/salmeterol xinafoate 25 μg (FP/SAL) is widely used in adults and children with asthma, but there is sparse information on its use in very young children. Methods: This was a randomized, double-blind, multicentre, controlled trial conducted in children aged 8 months to 4 years. During a 2-week run-in period, they all received FP twice daily. At randomization, they commenced FP/SAL or FP twice daily for 8 weeks. All were then given FP/SAL only, in a 16-week open-label study continuation. Medications were inhaled through an AeroChamber Plus with attached face mask. The primary end-point was mean change in total asthma symptom scores from baseline to the last 7 days of the double-blind period. Analyses were undertaken in all children randomized to treatment and who received at least one dose of study medication. Results: Three hundred children were randomized 1:1 to receive FP/SAL or FP. Mean change from baseline in total asthma symptom scores was –3.97 for FP/SAL and –3.01 with FP. The between-group difference was not statistically significant (P = 0.21; 95% confidence interval: −2.47, 0.54). No new safety signals were seen with FP/SAL. Conclusion: This is the first randomized, double-blind study of this size to evaluate FP/SAL in very young children with asthma. FP/SAL did not show superior efficacy to FP; no clear add-on effect of SAL was demonstrated. No clinically significant differences in safety were noted with FP/SAL usage.

AB - Background: Fluticasone propionate 50 μg/salmeterol xinafoate 25 μg (FP/SAL) is widely used in adults and children with asthma, but there is sparse information on its use in very young children. Methods: This was a randomized, double-blind, multicentre, controlled trial conducted in children aged 8 months to 4 years. During a 2-week run-in period, they all received FP twice daily. At randomization, they commenced FP/SAL or FP twice daily for 8 weeks. All were then given FP/SAL only, in a 16-week open-label study continuation. Medications were inhaled through an AeroChamber Plus with attached face mask. The primary end-point was mean change in total asthma symptom scores from baseline to the last 7 days of the double-blind period. Analyses were undertaken in all children randomized to treatment and who received at least one dose of study medication. Results: Three hundred children were randomized 1:1 to receive FP/SAL or FP. Mean change from baseline in total asthma symptom scores was –3.97 for FP/SAL and –3.01 with FP. The between-group difference was not statistically significant (P = 0.21; 95% confidence interval: −2.47, 0.54). No new safety signals were seen with FP/SAL. Conclusion: This is the first randomized, double-blind study of this size to evaluate FP/SAL in very young children with asthma. FP/SAL did not show superior efficacy to FP; no clear add-on effect of SAL was demonstrated. No clinically significant differences in safety were noted with FP/SAL usage.

KW - asthma

KW - child

KW - combination therapy

KW - double-blind

KW - fluticasone propionate

KW - randomized

KW - salbutamol

KW - salmeterol

UR - http://www.scopus.com/inward/record.url?scp=85061341826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061341826&partnerID=8YFLogxK

U2 - 10.1111/pai.13010

DO - 10.1111/pai.13010

M3 - Article

VL - 30

SP - 195

EP - 203

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

SN - 0905-6157

IS - 2

ER -